<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880695</url>
  </required_header>
  <id_info>
    <org_study_id>2018PHD008-01</org_study_id>
    <nct_id>NCT03880695</nct_id>
  </id_info>
  <brief_title>Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <acronym>ALTER-S001</acronym>
  <official_title>Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma : a One-arm, Multi-center, Prospective Clinical Trial (ALTER-S001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Shougang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in
      patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>each 42 days to evaluate up to intolerance the toxicity or PD (in first 24 weeks), each 84 days to evaluate up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Calculated from the date of treatment start until last follow-up or death, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization until death (up to 24 months)</time_frame>
    <description>Calculated from the date of treatment start until last follow-up or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 42 days to evaluate up to intolerance the toxicity or PD (in first 24 weeks), each 84 days to evaluate up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Overall objective response measured using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>each 42 days to evaluate up to intolerance the toxicity or PD (in first 24 weeks), each 84 days to evaluate up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Disease Control Rate measured using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>each 42 days to evaluate up to intolerance the toxicity or PD (in first 24 weeks), each 84 days to evaluate up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>QoL is measured by the World Health Organization Quality of Life (WHOQOL-BREF)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib+ Liposomal Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib Hydrochloride Combined With Liposomal Doxorubicin Liposomal Doxorubicin 50mg/m2 Day 1 every-3-weeks (Q3W) and Anlotinib 12mg QD po at Day 8-21 Q3W and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib+ Liposomal Doxorubicin</intervention_name>
    <description>Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks</description>
    <arm_group_label>Anlotinib+ Liposomal Doxorubicin</arm_group_label>
    <other_name>Anlotinib+ LPD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed the informed consent form prior to patient entry;

          -  ≥ 14 years of age , regardless of gender；ECOG :0-1;Expected Survival Time: Over 3
             months;

          -  Histologically confirmed diagnosis of un-resectable or recurrent metastatic soft
             tissue sarcoma, such as: leiomyosarcoma, synovial sarcoma, undifferentiated
             pleomorphic sarcoma, liposarcoma , angiosarcoma, alveolar soft tissue sarcoma, and
             other sarcomas. The following histologies are excluded: embryonic rhabdomyosarcoma,
             chondrosarcoma, osteosarcoma, gastrointestinal stromal tumor and Ewing sarcoma/primary
             neuroectodermal tumor.

          -  Previously without anthracyclines or other anti-tumor drugs

          -  Evaluable disease by imaging or physical exam or measurable disease defined as at
             least one lesion that can be accurately measured according to RECIST version 1.1.

          -  Normal main organs function as defined below: Hemoglobin (Hb) ≥ 80g / L, Neutrophils
             (ANC) ≥ 1.5 × 10^9 / L, Platelet count (PLT) ≥ 80 × 10^9 / L, Serum creatinine (Cr) ≤
             1.5 × normal upper limit (ULN) or creatinine clearance (CCr) ≥ 60ml / min, Blood urea
             nitrogen (BUN) ≤ 2.5 × normal upper limit (ULN); Total bilirubin (TB) ≤ 1.5 × ULN;
             Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; If
             accompanied by liver metastases, ALT and AST ≤ 5 × ULN Albumin (ALB) ≥ 25 g/L. Doppler
             ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ normal low limit
             (50%)

          -  Women of childbearing potential should agree to use and utilize an adequate method of
             contraception (such as intrauterine device，contraceptive and condom) throughout
             treatment and for at least 6 months after study is stopped；the result of serum or
             urine pregnancy test should be negative within 7 days prior to study enrollment，and
             the patients required to be non-lactating；Man participants should agree to use and
             utilize an adequate method of contraception throughout treatment and for at least 6
             months after study is stopped.

        Exclusion Criteria:

          -  Prior treatment with anlotinib or any other VEGFR tyrosine kinase inhibitor (such as
             sunitinib, sorafenib, bevacizumab, imatinib, famitinib, apatinib, regorafenib and
             other drugs).

          -  Systemic anti-tumor therapy, including cytotoxic therapy, signal transduction
             inhibitors, and immunotherapy, is planned for the first 4 weeks prior to enrollment or
             during the study. Radiation radiotherapy (EF-RT) was performed within 4 weeks prior to
             enrollment.

          -  A history of other malignancy ≤ 3 years previous

          -  Known central nervous system metastases.

          -  Imaging (CT or MRI) shows tumor lesions from large vessels ≤ 5 mm, the tumor is very
             likely to invade the important blood vessels and cause fatal hemorrhage, or the
             formation of tumor thrombosis with large veins (iliac vessels, inferior vena cava,
             pulmonary veins, superior vena cava);

          -  The investigator judged that the presence of distinct pulmonary cavitary or necrotic
             tumors;

          -  Serosal effusion with clinical symptoms requiring surgical management (including
             hydrothorax and ascites pericardial effusion)

          -  With uncontrollable hypertension (systolic blood pressure ≥140 mmHg or diastolic blood
             pressure ≥90 mmHg, despite optimal drug treatment).

          -  Arrhythmias with grade II and above myocardial ischemia or myocardial infarction, poor
             control (including corrected QT interval(QTc) men ≥ 450 ms, women ≥ 470 ms).

          -  According to NYHA criteria, grade III to IV cardiac insufficiency, or cardiac color
             Doppler ultrasound examination showed left ventricular ejection fraction (LVEF) &lt;50%,
             myocardial infarction occurred within 6 months before enrollment, ≥ 2 congestive heart
             failure (New York Heart Association ( NYHA) rating ), uncontrolled angina, clinical
             pericardial disease, or electrocardiogram suggesting acute ischemia or active
             conduction system abnormalities.

          -  Uncontrolled comorbid diseases, including but not limited to: poorly controlled
             diabetes, persistent active infections, or mental illness or social condition that may
             affect a subject's adherence to the study.

          -  Patients with active hepatitis B or hepatitis C (hepatitis B: HBsAg-positive and
             hepatitis B virus(HBV) DNA ≥ 500 IU/mL; hepatitis C: hepatitis C virus(HCV)
             RNA-positive and abnormal liver function), or active infection requiring antimicrobial
             treatment (eg Treated with antibacterial drugs, antiviral drugs, antifungal drugs)

          -  Renal insufficiency: urine routine indicates urinary protein ≥ ++, or confirmed
             24-hour urine protein ≥ 1.0 g;

          -  Patients with seizures and need treatment

          -  Abnormal coagulation (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN + 4 seconds or
             activated partial thromboplastin time(APTT) &gt; 1.5 ULN), with bleeding tendency or
             undergoing thrombolytic or anticoagulant therapy.

          -  Patients treated with anticoagulants or vitamin K antagonists such as warfarin,
             heparin.

          -  Significant coughing blood in the 2 months before enrollment, or daily hemoptysis of
             2.5ml or more.

          -  History of psychotropic substance abuse who are unable to quit or have a mental
             disorder.

          -  Tendencies of hereditary or acquired hemorrhagic and thrombotic (such as hemophilia
             patients, coagulopathy, thrombocytopenia, hypersplenism, etc.)

          -  Any major unhealed wound, ulcer, or fracture occurred in a patient who had undergone
             major surgery or trauma within 4 weeks prior to enrollment.

          -  Active period digestive ulcers.

          -  Cavity sinus or perforation occurred within 6 months.

          -  Participated in other anti-tumor clinical trials within 4 weeks.

          -  Received a potent CYP3A4 inhibitor (such as ketoconazole, itraconazole, erythromycin,
             and clarithromycin) within 7 days, or received a potent CYP3A4 inducer within 12 days
             prior to the study (eg. catarrh Treatment with imipramine, rifampicin and
             phenobarbital).

          -  Allergic reactions, hypersensitivity reactions or intolerance to anlotinib
             hydrochloride or its excipients.

          -  Pregnancy or lactation.

          -  The investigator believes that there are any conditions that may damage the subject or
             result in the subject not being able to meet or perform the research request.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Guo, MD</last_name>
    <phone>+86-13701195504</phone>
    <email>bonetumor@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Sun</last_name>
    <phone>+86-10-66583761</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin Gu</last_name>
      <email>zlgujin@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jie Xu, M.D.</last_name>
      <email>xujie_pkuph@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhengfu Fan</last_name>
      <email>zhengfufan@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Guo</last_name>
      <phone>+86-10-66583761</phone>
      <email>bonetumor@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin Sun</last_name>
      <phone>+86-10-66583761</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xian'an Li</last_name>
      <email>lixianan2001@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Di Wu</last_name>
      <email>Wudi888991@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Tumor Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaojing Zhang</last_name>
      <email>zhangxiaojingwu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weibin Zhang</last_name>
      <email>zhangweibin10368@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guowen Wang</last_name>
      <email>wgwhrb@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>GUO WEI</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

